I haven't followed them closely but I was surprised to see the PR state the possibility of more trials given the P value. I thought the debate would be around a new REMS? Is it because they want a trial comparing against currently approved drugs? At any rate the stock seems to be holding up quite well.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.